Andrew McConaghie from Scrip spoke to Prof. Mauro Giacca, scientific founder of Forcefield and Richard Francis, CEO,on the company’s novel platform for discovering protective tissue factors and turning them into therapies, with heart failure as its first target as well as our goal of developing a protein-based therapy for acute myocardial infarction (MI) to preserve heart cells which would otherwise be lost and cause irreparable heart failure.
About Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes. Forcefield Tx was founded by scientists, industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI).
Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by leading FTSE 250 healthcare company, Syncona.
